Growth potential Target growth opportunities from Saptalis’s mid-sized specialty portfolio and recent product launches, focusing on neurology and oncology formulations to expand within hospital systems, specialty pharmacies, and oncology centers.

Product expansion Leverage Saptalis’s active development of next‑generation formulations and recent launches such as chlorpromazine HCl oral concentrate, cyclosporine ophthalmic emulsion, and fluoxetine oral solution to cross-sell adjacent sterile and non‑sterile liquid and semi‑solid products to existing customers and new markets.

Therapeutic focus Push BD efforts around neurology and oncology formulations highlighted by partnerships with AI for coformulation, presenting opportunities to position Saptalis as a preferred development and manufacturing partner for specialty therapies and reformulations.

Regulatory readiness Emphasize FDA‑approved cGMP facilities in Hauppauge as a selling point to add prospective clients seeking compliant manufacturing for sterile and non‑sterile liquids and semi‑solids, especially for faster time‑to‑market collaborations.

Strategic partnerships Explore collaborations with contract research and optimization partners, wholesalers, and healthtech ecosystems given Saptalis’s software and digital footprint (WordPress, WooCommerce, Microsoft 365) to streamline partnerships and provide scalable, transparent procurement and supply chain solutions.